Live Breaking News & Updates on Software Essen Bioscience

Science for just $15 USD.
Short circuiting solid tumors
Two major hurdles in chimeric antigen receptor (CAR) T cell therapy for solid tumors are ensuring specificity to tumor cells without affecting healthy cells and avoiding tumor escape due to antigen loss. To address these challenges, Hyrenius-Wittsten
et al. and Choe
et al. developed synthetic Notch (synNotch)–CAR T cells targeting solid tumor antigens and used them to treat mouse models of mesothelioma, ovarian cancer, and glioblastoma. In both studies, the authors demonstrated that synNotch-CAR T cells were better at controlling tumors than traditional CAR T cells and did not result in toxicity or damage to healthy tissue. These results suggest that synNotch-CAR T cells may be an effective treatment strategy for solid tumors. ....

United Kingdom , Takara Bio , Facsaria Iiiu , Chan Zuckerberg Biohub , Celltrace Violet , B Ebert Addgene , Essen Bioscience , P Steinberger Addgene , Swedish Society For Medical Research , National Cancer Institute , Transfection Reagent Mirus Bio , Kleberg Foundation , Worthington Biochemical Corporation , Software Essen Bioscience , Swedish Research Council , Cancer Research United Kingdom , Graphpad Software , Parker Institute For Cancer Immunotherapy , Ge Healthcare , Helen Diller Family Comprehensive Cancer Center , Hitrap His , Vector Laboratories , Jackson Immunoresearch Laboratories , Thermo Fisher Scientific , Lenti Transfection Reagent , Mirus Bio ,